Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma

J. Vymazal, T. Kazda, T. Novak, P. Slanina, J. Sroubek, J. Klener, T. Hrbac, M. Syrucek, AM. Rulseh

. 2022 ; 12 (-) : 1014455. [pub] 20230119

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23003129

INTRODUCTION: The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150-300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients' scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9-77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0-76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected. RESULTS: Patients on TTFields therapy demonstrated improvements in PFS and OS relative to controls (hazard ratio: 0.64, p=0.031; and 0.61, p=0.028 respectively). TTFields average time on therapy was 74.8% (median 82%): median PFS of these patients was 19.75 months. Seven patients with TTFields usage ≤60% (23-60%, mean 46.3%, median 53%) had a median PFS of 7.95 months (p=0.0356). Control patients with no TTFields exposure had a median PFS of 12.45 months. Median OS of TTF patients was 31.67 months compared to 24.80 months for controls. DISCUSSION: This is the most extensive study on newly-diagnosed GBM patients treated with TTFields, covering a period of 18 years at a single center and presenting not only data from clinical trials but also a group of 36 patients treated with TTFields as a part of routine clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003129
003      
CZ-PrNML
005      
20230421100004.0
007      
ta
008      
230413s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2022.1014455 $2 doi
035    __
$a (PubMed)36741707
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vymazal, Josef $u Department of Radiology and Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czechia
245    10
$a Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma / $c J. Vymazal, T. Kazda, T. Novak, P. Slanina, J. Sroubek, J. Klener, T. Hrbac, M. Syrucek, AM. Rulseh
520    9_
$a INTRODUCTION: The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150-300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients' scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9-77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0-76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected. RESULTS: Patients on TTFields therapy demonstrated improvements in PFS and OS relative to controls (hazard ratio: 0.64, p=0.031; and 0.61, p=0.028 respectively). TTFields average time on therapy was 74.8% (median 82%): median PFS of these patients was 19.75 months. Seven patients with TTFields usage ≤60% (23-60%, mean 46.3%, median 53%) had a median PFS of 7.95 months (p=0.0356). Control patients with no TTFields exposure had a median PFS of 12.45 months. Median OS of TTF patients was 31.67 months compared to 24.80 months for controls. DISCUSSION: This is the most extensive study on newly-diagnosed GBM patients treated with TTFields, covering a period of 18 years at a single center and presenting not only data from clinical trials but also a group of 36 patients treated with TTFields as a part of routine clinical practice.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Novak, Tomas $u Department of Radiation Oncology, Central Military Hospital and Faculty Hospital Motol, Prague, Czechia
700    1_
$a Slanina, Petr $u Department of Radiology and Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czechia
700    1_
$a Sroubek, Jan $u Department of Neurosurgery, Na Homolce Hospital, Prague, Czechia
700    1_
$a Klener, Jan $u Department of Neurosurgery, Na Homolce Hospital, Prague, Czechia
700    1_
$a Hrbac, Tomas $u Department of Neurosurgery, Faculty Hospital Ostrava, Ostrava, Czechia
700    1_
$a Syrucek, Martin $u Department of Pathology, Na Homolce Hospital, Prague, Czechia
700    1_
$a Rulseh, Aaron M $u Department of Radiology and Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 1014455
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36741707 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421095957 $b ABA008
999    __
$a ok $b bmc $g 1922781 $s 1189336
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 12 $c - $d 1014455 $e 20230119 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20230413

Find record

Citation metrics

Archiving options